Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.61 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | HPGD | P15428 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 7/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.50 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27646876 | 0.89 | KMT2A (0.52) | KMT2AMEN1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL11289405 | 0.82 | KMT2A (0.81) | KMT2AMEN1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL11768785 | 0.81 | KMT2A (0.55) | KMT2AMEN1HPGDMAPTSMN1; SMN2 | |
| Dibenzoylmethane SCHEMBL11176186 | 0.79 | KMT2A (0.74) | KMT2AMEN1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL9316324 | 0.78 | KMT2A (0.69) | KMT2AMEN1HPGDMAPTSMN1; SMN2 | |
| Dibenzoylmethane SCHEMBL39582 | 0.78 | MEN1 (1.00) | KMT2AMEN1HPGDMAPTSMN1; SMN2 | |
| Dibenzoylmethane SCHEMBL10356288 | 0.78 | MEN1 (1.00) | KMT2AMEN1HPGDMAPTSMN1; SMN2 | |
| Dibenzoylmethane SCHEMBL1704711 | 0.78 | MEN1 (1.00) | KMT2AMEN1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL38900 | 0.78 | KMT2A (0.65) | KMT2AMEN1HPGDMAPTSMN1; SMN2 | |
| Dibenzoylmethane SCHEMBL5680105 | 0.78 | KMT2A (0.65) | KMT2AMEN1HPGDMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6355264-B1 | WATER RESISTANT/WATERPROOF PROPERTIES | AVON PRODUCTS, INC. | 2002-03-12 | — | — | US | claimed |
| US-8912165-B2 | Methods of skin treatment and use of water-soluble β-(1,3) glucans as active agents for producing therapeutic skin treatment agents | BIOTEC PHARMACON ASA (NO) | 2014-12-16 | — | — | US | disclosed |
| US-20130296265-A1 | Methods of Skin Treatment and Use of Water-Soluble Beta-(1,3) Glucans as Active Agents for Producing Therapeutic Skin Treatment Agents | BIOTEC PHARMACON ASA (NO) | 2013-11-07 | — | — | US | disclosed |
| US-8501710-B2 | Antiulcer agents; wound healing agents | BIOTEC PHARMACON ASA (NO) | 2013-08-06 | — | — | US | disclosed |
| WO-2011051712-A1 | SECURITY DOCUMENT | THE GOVERNOR & COMPANY OF THE BANK OF ENGLAND (GB) | 2011-05-05 | — | — | WO | disclosed |
| US-20080220031-A1 | Dermocosmetic Preparations | BASF AKTIENGESELLSCHAFT (DE) | 2008-09-11 | — | — | US | disclosed |
| WO-2007123699-A1 | METHODS AND COMPOSITIONS FOR MODULATING MELANOGENESIS BY USING A MCLR AGONIST | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070104676-A1 | Cosmetic and/or dermatological preparations containing an extract from the seeds of plants of the genus adenanthera | COGNIS FRANCE S.A. (FR) | 2007-05-10 | — | — | US | disclosed |
| US-20060194760-A1 | Cosmetic preparations | BIOTEC ASA (NO) | 2006-08-31 | — | — | US | disclosed |
| US-6964775-B1 | Decorative cosmetic preparations | BIOTEC ASA (NO) | 2005-11-15 | — | — | US | disclosed |
| US-6858214-B1 | Use of nanoscalar water-soluble β-(1,3) glucans | BIOTEC ASA (NO) | 2005-02-22 | — | — | US | disclosed |
| US-20050009781-A1 | Methods of skin treatment and use of water-soluble beta-(1,3) glucans as active agents for producing therapeutic skin treatment agents | BIOTEC PHARMACON ASA (NO) | 2005-01-13 | — | — | US | disclosed |
| US-6706696-B1 | MIXTURES OF SPECIFIC GLUCANS AND NUCLEIC ACIDS | BIOTEC ASA (NO) | 2004-03-16 | — | — | US | disclosed |
| US-20030180278-A1 | Use of a combination of active substances containing bioquinones for the production of cosmetic or dermatological preparations | GS DEVELOPMENT A.B. (SE) | 2003-09-25 | — | — | US | disclosed |
| US-6500410-B1 | IMPROVING THE PHOTO SENSITIVITY AND SOLUBILITY OF UV LIGHT PROTECTION FACTOR IN SUN PROTECTING AGENTS COMPRISING INCLUDING WATER SOLUBLE BETA-(1,3) GLUCANS WHICH ARE SUBSTANTIALLY FREE FROM BETA-(1,6) LINKAGES | BIOTEC PHARMACON ASA (NO) | 2002-12-31 | — | — | US | disclosed |
| US-6497863-B1 | PREPARATION COMPRISING WATER SOLUBLE BETA-(1,3) GLUCANS, WHICH ARE SUBSTANTIALLY FREE FROM BETA-(1,6) LINKAGES, ALUMINUM CHLOROHYDRATE, ESTERASE INHIBITORS, AND/OR BACTERICIDAL, RESPECTIVELY BACTERIOSTATIC, AGENTS | BIOTEC PHARMACON ASA (NO) | 2002-12-24 | — | — | US | disclosed |
| US-6497865-B1 | PREPARATIONS CONTAINING WATER SOLUBLE BETA-(1,3) GLUCANS, SUBSTANTIALLY FREE FROM BETA-(1,6) LINKAGES, AND POLYMERS; DECREASES TENDENCY TO FORMING OF STRESS CRACKS | BIOTEC PHARMACON ASA (NO) | 2002-12-24 | — | — | US | disclosed |
| US-6448304-B1 | POLYURETHANE, POLYTHIOURETHANE OR DIETHYLENE GLYCOL BISALLYLCARBONATE POLYMER; DIPPING IN SOLUTION CONTAINING A DIBENZOYLMETHANE OR A BENZOTRIZOLE COMPOUND; PLASTIC LENS FOR SPECTACLES WHICH ABSORBS ULTRAVIOLET RAYS; LOW YELLOWNESS | HOYA CORPORATION (JP) | 2002-09-10 | — | — | US | disclosed |
| US-6355264-B1 | WATER RESISTANT/WATERPROOF PROPERTIES | AVON PRODUCTS, INC. | 2002-03-12 | — | — | US | disclosed |
| WO-2001074302-A1 | PROLIPOSOMAL ENCAPSULATED PREPARATIONS | COGNIS IBERIA, S.L. (ES) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030180278-A1 | Use of a combination of active substances containing bioquinones for the production of cosmetic or dermatological preparations | SDHA, SDHB, SLC25A20 | KMT2A 1702/4885MEN1 1456/4885HPGD 223/4885 |
| US-20080220031-A1 | Dermocosmetic Preparations | C3AR1, C1S, C1R | KMT2A 3446/4885MEN1 247/4885HPGD 827/4885 |
| US-20060194760-A1 | Cosmetic preparations | GLA, CHIT1, ALG1 | KMT2A 3827/4885MEN1 92/4885HPGD 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.